Sensei Biotherapeutics to Present at Upcoming Conferences
BOSTON - Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a prominent player in the clinical stage of immuno-oncology, dedicated to developing innovative therapies for cancer patients. The company is thrilled to share that its management team will be presenting at several key conferences next month.
Event Highlights
The first event is the H.C. Wainwright 26th Annual Global Investment Conference, where Sensei Biotherapeutics will deliver a corporate presentation on September 9, 2024. This presentation is scheduled for 7:00 a.m. ET and will be available both virtually and in-person in New York.
2024 Cantor Fitzgerald Global Healthcare Conference
Following this, Sensei Biotherapeutics will take part in the 2024 Cantor Fitzgerald Global Healthcare Conference, featuring a fireside chat on September 18, 2024, at 2:30 p.m. ET, also in New York.
Webcasts and Replays
Both presentations will be streamed live and can be accessed in the Investors section of the Sensei Biotherapeutics website. Replays will be available for 90 days after the events, providing an opportunity for individuals to learn more about the company's innovative strategies and product pipeline.
About Sensei Biotherapeutics
Leading the charge in immuno-oncology, Sensei Biotherapeutics (Nasdaq: SNSE) is committed to transforming treatment options through its proprietary TMAb™ (Tumor Microenvironment Activated biologics) platform. This platform is designed to create conditionally active therapeutics that either target immunosuppressive signals or boost immunostimulatory signals within the tumor microenvironment.
Key Therapeutics in Development
Among its most promising investigational candidates is SNS-101, which specifically blocks the V-domain Ig suppressor of T cell activation (VISTA) in the low pH tumor environment. This strategy leverages the unique characteristics of cancer cells to effectively counteract T cell inhibition. Additionally, Sensei is progressing with SNS-102, a monoclonal antibody aimed at VSIG-4, and SNS-103, which targets CD39 with ecto-nucleoside triphosphate diphosphohydrolase-1 specificity. Another noteworthy candidate, SNS-201, combines a CD28 agonist with an anti-VISTA component to form a bispecific antibody that enhances therapeutic effectiveness.
Stay Connected
To learn more about the groundbreaking work at Sensei Biotherapeutics and their array of cancer therapies, please visit their website and connect with the company on various platforms, including X @SenseiBio and LinkedIn.
Contact Information
Investor Contact:
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
mbiega@senseibio.com
Media Contact:
Joyce Allaire
LifeSci Advisors
Jallaire@lifesciadvisors.com
Frequently Asked Questions
What is Sensei Biotherapeutics focused on?
Sensei Biotherapeutics is dedicated to developing next-generation immuno-oncology therapies that aim to enhance treatment options for cancer patients.
When will Sensei present at the H.C. Wainwright Conference?
Sensei will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 7:00 a.m. ET.
What is the TMAb™ platform?
The TMAb™ platform developed by Sensei focuses on creating therapeutics that can activate or inhibit immune responses directly within the tumor microenvironment.
Can I watch the presentations later?
Yes, both presentations will be available as webcasts and can be replayed for up to 90 days following the events.
How can I stay updated on Sensei's activities?
You can stay informed about Sensei Biotherapeutics by visiting their website and following them on X @SenseiBio and LinkedIn for the latest news and updates.